Ningxia Qiyuan Pharmaceutical Co., Ltd. was established in January 2001, by the former state-owned enterprise Ningxia Pharmaceutical Factory and Ningxia Traditional Chinese Medicine Factory. The company adheres to the inheritance and seizes the opportunity. After nearly two decades of unremitting efforts, the company has now developed into a modern large-scale comprehensive biopharmaceutical enterprise well-known at home and abroad.

             The company relies on Ningxia's regional advantages suitable for the development of biopharmaceuticals, and vigorously develops the development and production of antibiotic raw materials, vitamin raw materials, and deep processing of corn. The company's tetracycline API series products are exclusive products in the world. Erythromycin API and its synthetic products are currently one of the world's three largest suppliers. Vitamin C series products occupy a place in the domestic and foreign markets due to their scale and quality.

             The company pays attention to product quality and product research and development, and is listed as a national high-tech enterprise. The company's technology center is a national enterprise technology center. Erythromycin and tetracycline hydrochloride raw materials have passed the US FDA, European COS and EUGMP certification, as well as official quality audits in India, Japan and other countries. The company's vitamin C products have passed international food certifications, such as HALAL, KOSHER, etc. The company's products are sold in dozens of countries and regions in Europe, South America, Africa, Southeast Asia and so on. The company's "Qiyuan" registered trademark has been recognized as "Ningxia Famous Trademark" by the Ningxia Hui Autonomous Region Administration for Industry and Commerce many times.

             The company has been awarded the titles of "AAA-level Integrity Pharmaceutical Enterprise" in the autonomous region, "A-level tax-paying credit unit" in the autonomous region, and "contract-honoring and trustworthy enterprise" of the state, autonomous region, and Yinchuan City. 



            Ningxia Qiyuan Chinese Medicine Co., Ltd. is a wholly-owned subsidiary invested by Qiyuan. It is a national-level high-tech enterprise integrating scientific research and production. The company has advanced production and testing equipment, and a complete quality assurance system. The company has an autonomous region-level enterprise. Technology center, the company as a whole has passed the national new version of GMP certification. After years of continuous technological progress and development, it has become the largest manufacturer of preparations in the pharmaceutical industry in the region. "Qiyuan" brand products enjoy a good reputation and credibility in the market.

            Qiyuan Chinese Medicine currently has 245 employees, including 110 pharmacy professionals and 8 licensed pharmacists. In 2018, it achieved sales revenue of 113 million yuan. The company's characteristic products include Jinlian Qingre Granules, Hawthorn Extract Lipid-lowering Tablets, Qi Rong Tablets, Jin Jingkang, Matrine Suppositories, Qi Sheng Capsules, Fuxin Tablets, Liuwei Dihuang Pills, Xiaoshi Jianwei Tablets, etc. Among them, Jinlian Qingre Granules and Jinlian Qingre Capsules are exclusively produced medicines. The national protected varieties of traditional Chinese medicines and Ningxia famous brand products are listed as national reserve drugs that are urgently needed for public health accidents, major disasters, and epidemics due to their remarkable efficacy. The sales of specialty preparation products radiate 28 provinces, municipalities and autonomous regions across the country.

           The company is a "little giant" enterprise in Yinchuan City and an advanced tax payment enterprise at the autonomous region level. For many consecutive years, it has been awarded the title of "Contract-honoring and Credit-keeping" Enterprise at the national, district and municipal levels, "Yinchuan Social Insurance Credit Unit", and "High-tech Enterprise".



            Ningxia Qiyuan Medicine Co., Ltd. is a wholly-owned subsidiary invested by Qiyuan. It integrates pharmaceutical distribution, wholesale, and retail chains. It is a national contract-abiding and trustworthy unit and an autonomous region’s tax-paying credit unit. It has opened 9 directly-operated chain pharmacies in the region . There are 110 employees, including 71 medical professionals, accounting for 63% of the total number, and 10 licensed pharmacists.

            The company mainly deals in Chinese patent medicines, Chinese medicinal materials, Chinese herbal medicines, chemical raw materials and their preparations, antibiotics and their preparations, biochemical drugs, biological products, second-class psychotropic drugs, anabolic preparations and peptide hormones, medical devices, etc. In 2018, it achieved sales revenue of 65 million yuan. There are 12 existing delivery vehicles (including 1 refrigerated vehicle); the distribution warehouse area with self-owned property rights is 7,336 square meters (including 80 cubic meters of cold storage), with room temperature storage, shade storage, cold storage, traditional Chinese medicine decoction storage, and medical equipment Storage and maintenance conditions for all kinds of medicines, equipment and medical consumables, etc. The company has a sound quality management system and a complete system. It has passed the new version of GSP certification in 2014. The warehousing facilities are complete and equipped with automatic temperature and humidity monitoring system, automatic temperature control and humidification equipment, all-round electronic monitoring system, etc. A professional distribution management information platform integrating distribution, warehousing, finance and GSP has been established, which has greatly improved the level of corporate management. The company has a complete information management system, which can realize the entire quality control of drug purchase, storage, and sales. The company was rated as "2018 Yinchuan City Adverse Drug Reaction Monitoring Work Advanced Group" and "Ningxia Pharmaceutical Industry Association-Vice President Unit".



            Ningxia Yuyuan Biological Technology Co., Ltd. was registered and established in October 2014. (Yuyuan Biological for short) is a wholly-owned subsidiary invested and established by Ningxia Qiyuan Pharmaceutical Co., Ltd. with a registered capital of 20 million yuan. It is mainly engaged in deep processing of corn A high-tech biochemical enterprise. The main products are starch (starch milk), glucose (liquid sugar), sorbitol and its by-product corn gluten meal, corn germ, corn husk, corn syrup; soybean meal powder, soybean meal powder; hydrogen gas, etc.

            The company introduced international leading technology and invested more than 200 million yuan to build 200,000 tons of starch production lines, 150,000 tons of glucose production lines, 50,000 tons of sorbitol production lines and an annual output of 750,000 cubic meters of hydrogen filling stations. It adopts automated equipment, advanced production technology, sophisticated testing equipment and perfect quality assurance system. Adhering to the quality management concept of "products in hand, quality in heart", it has won high recognition and reputation from customers with its excellent quality and excellent service.

           Traveling far away must be self-conscious, and the pursuit is endless. With the business philosophy of "building reputation, improving efficiency, increasing efficiency, and sustainability", the company continuously optimizes product structure, extends the industrial chain, and increases product value-added innovation and development ideas, and sincerely cooperates with customers for a win-win situation and creates brilliance.

Product Center


View more+